VYYRF Stock Chart & Stats
$0.10
$0.00(0.00%)
At close: 4:00 PM EDT
$0.10
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.20
Previous CloseN/A
Volume10.00K
Average Volume (3M)5.52K
Market Cap
$27.66M
Enterprise Value$14.81
Total Cash (Recent Filing)$441.87K
Total Debt (Recent Filing)$40.00K
Price to Earnings (P/E)―
Beta-20.10
Next Earnings
Nov 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding226,342,350
10 Day Avg. Volume7,500
30 Day Avg. Volume5,516
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)21.82
Price to Sales (P/S)2339.21
P/FCF Ratio-9.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Early Revenue GrowthHigher TTM revenue indicates initial commercial traction in the company’s barite and pharmaceutical-materials activities. Although the base is very small, sustained sales conversion could support operating leverage over the medium term.
Low Financial LeverageVery low leverage limits interest and refinancing pressure, preserving financial flexibility while the company develops its products. This provides a stronger balance-sheet foundation than a similarly loss-making business carrying substantial debt.
Value-Added Product FocusProcessing barite into pharmaceutical-grade or otherwise specified barium sulfate products offers a potential value-added route beyond raw-material sales. Product qualification and specialization could support customer relevance and more durable margins if commercial scale is achieved.
Bears Say
Severe UnprofitabilityLarge gross and net losses show that the current cost base substantially exceeds the company’s very limited revenue. Until sales scale materially or expenses decline, persistent losses will constrain reinvestment and increase dependence on external capital.
Continued Cash BurnNegative operating and free cash flow means operations are not self-funding and continue to consume capital. Even with improved burn versus the prior annual period, ongoing cash deficits create sustained funding needs and execution risk over the medium term.
Eroding Equity BaseMaterial shareholder-equity erosion reflects the cumulative effect of ongoing losses and weak returns on capital. A shrinking capital base reduces resilience and may force future financing, potentially limiting strategic flexibility while the business remains pre-scale.
Voyageur Pharmaceuticals News
VYYRF FAQ
What was Voyageur Pharmaceuticals’s price range in the past 12 months?
Voyageur Pharmaceuticals lowest stock price was $0.01 and its highest was $0.20 in the past 12 months.
What is Voyageur Pharmaceuticals’s market cap?
Voyageur Pharmaceuticals’s market cap is $27.66M.
When is Voyageur Pharmaceuticals’s upcoming earnings report date?
Voyageur Pharmaceuticals’s upcoming earnings report date is Nov 02, 2026 which is in 65 days.
How were Voyageur Pharmaceuticals’s earnings last quarter?
Voyageur Pharmaceuticals released its earnings results on Jul 24, 2026. The company reported -$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Voyageur Pharmaceuticals overvalued?
According to Wall Street analysts Voyageur Pharmaceuticals’s price is currently Overvalued.
Does Voyageur Pharmaceuticals pay dividends?
Voyageur Pharmaceuticals does not currently pay dividends.
What is Voyageur Pharmaceuticals’s EPS estimate?
Voyageur Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Voyageur Pharmaceuticals have?
Voyageur Pharmaceuticals has 226,342,350 shares outstanding.
What happened to Voyageur Pharmaceuticals’s price movement after its last earnings report?
Voyageur Pharmaceuticals reported an EPS of -$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Voyageur Pharmaceuticals?
Currently, no hedge funds are holding shares in VYYRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. specializes in the creation of mineral-based active pharmaceutical ingredients (APIs). The company aims to produce radiocontrast agents utilizing barium and iodine, along with pharmaceutical products derived from bromine. It possesses complete ownership of three barium sulfate deposits in British Columbia, Canada, two of which are of a quality appropriate for the pharmaceutical barite sector. Furthermore, Voyageur holds stakes in a valuable brine project in Utah, United States, known for its high concentrations of iodine, lithium, and bromine. The company transitioned from its previous name, Voyageur Minerals Ltd., to Voyageur Pharmaceuticals Ltd. in December 2019. Its corporate headquarters are located in Calgary, Canada.